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When  stringent  criteria  have  been  used,  the  Epstein  Barr  virus  (EBV),  the  Kaposi’s  sarcoma  herpesvirus
(KSHV),  human  immunodeﬁciency  virus type  1 (HIV-1)  and human  hepatitis  C virus  (HCV)  have  been
identiﬁed  with  sufﬁcient  evidence  to be causative  agents  of  non-Hodgkin’s  Lymphomas.  Initially,  sin-
gle viral  infection  was  considered  fully  responsible  for the  oncogenic  properties  of each  virus,  while it  is
now established  that  in many  cases,  multiple  viral  agents  collaborate  as  cofactors  in inducing  lymphomas,
especially  in  the  presence  of  HIV-dependent  immunodeﬁciency.  Viruses  cooperate  by using  their  speciﬁc
pathogenetic  mechanisms  in  different  combinations.  The  aim  of this  review  is  to describe  the  cooperation
between  different  viruses  in  the  development  of lymphomas  including  the  evidences  supporting  their
pathogenetic  role.  Viral  cooperation,  a mechanism  by  which  different  viruses  coinfecting  human  tissues
have  synergistic  or regulatory  effects  on  carcinogenesis,  targets  neoplastic  B cells  as well as  cells  of  the
microenvironment,  such  as  reactive  T-cells,  B  cells  and  macrophages,  as well  as  non-immune  cells  such  as
endothelial  cells,  that contribute  to  tumor  microenvironment.  The  most  important  viral  genes  involved
in cooperation  include  HIV-1  tat  and  vpu, EBV  LMP-1  and  EBNA-2  and  KSHV  KIE2,  Rta  and  LANA.  Lym-
phomagenesis  related  to  viral  cooperation  represents  an  interesting  topic  where  microenvironmental
abnormalities  may  be  particularly  relevant,  particularly  because  antiviral  targeted  therapies  and  ther-
apies  producing  the  reconstitution  of  the  immune  system  may  constitute  areas  of  interest  aiming  at
improving  the  outcome  of  virus associated  lymphomas.  While  the immune  component  of the  lymphoma
microenvironment  can  be easily  studied  by  immunological  and  molecular  techniques,  the  deﬁnition  of the
non-immune  component  of the lymphoma  microenvironment  is  largely  incomplete  and may  be  the  issue
of future  investigations.  Understanding  the  pathogenetic  role  of viral  infection  in  speciﬁc  malignancies
and  deﬁning  microenvironmental  abnormalities  and  mechanisms  of  viral  carcinogenesis  are  important
steps  toward  precise  diagnosis  and  accurate  treatment  strategies  for  HIV-associated  cancers.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Infectious agents play an important role in the etiopatho-
enesis of non-Hodgkin and Hodgkin Lymphomas [1,2]. It is
ncreasingly evident that appropriately deﬁning appropriately
nfection-associated cancers is mandatory to improve cancer pre-
ention, diagnosis and research and that characterizing these
umors with respect to genomic features is essential in order to
ptimize treatments. Very recently, Gopal et al. issued a prospec-
ive view on this topic and correctly claimed that pathologic and
olecular identiﬁcation of oncogenic viruses in tumor specimens
∗ Corresponding author at: Scientiﬁc Directorate, Centro di Riferimento Onco-
ogico, IRCCS, Via Gallini 2, 33081, Italy. Tel.: +39 0434659282; fax: +39 0434659527.
E-mail address: dirscienti@cro.it (P. De Paoli).
ttp://dx.doi.org/10.1016/j.semcancer.2015.03.009
044-579X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
is necessary to classify infection-related cancers [3]. However,
due to the widespread diffusion of many potential oncogenic
viruses infecting humans and the relatively low incidence of
related cancers, establishing their effective oncogenic roles remains
challenging. In fact, in reviewing the international literature on
virus-associated cancers, we had previously found that many
published studies do not provide enough details about the patho-
logic features or the molecular characteristics of the malignant
specimens [4]. A portion of the studies on cancers classiﬁed as
infection-related reported the detection of a virus in tumor tis-
sue by polymerase chain reaction, without evidencing whether
or not it infects the tumor cells. Only a few studies reported
results obtained by in situ methods showing the virus within indi-
vidual tumor cells. For these reasons, we have emphasized that
strict diagnostic criteria must be used to establish associations
between viruses and cancers, a strategy that could help to deﬁne
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table  1
Virus associated lymphomas assessed by the IARC Monograph Working Group.
Pathogenetic mechanism Viruses involved Mechanisms of action
Direct action EBV Induction of growth signals
Inhibition of apoptosis
Genomic instability
KSHV Inhibition of apoptosis
Genomic instability
HTLV 1 Tax-dependent cell proliferation and transformation
Chronic antigenic stimulation/inﬂammation HIV B cell stimulation via P24 antigen, CD40L
EBV IL-10 production
HCV HCV E2 B cell stimulation and engagement of IL-2 production by T cells
HBV  Not deﬁned
Immunodeﬁciency HIV T helper cell depletion
Treg cell depletion
Cytokine dysregulation
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ore precisely several controversial issues existing in this ﬁeld
5].
When these stringent criteria have been used, the Epstein Barr
irus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV)
ave been identiﬁed with sufﬁcient evidence to be causative agents
f NHL, and EBV has been consistently related to different forms of
ymphoma [2]. For other viruses evidence is still present, but more
imited or indirect, such as for HIV-1, Hepatitis Viruses B and C
2,4,6]. Three general pathogenetic mechanisms of viral-associated
ymphomagenesis have been identiﬁed: ﬁrst, some viruses, such as
BV and KSHV, directly infect and transform lymphocytes; second,
iral antigenic products or soluble factors induce chronic B cell acti-
ation and promote cellular transformation; and third, prolonged
mmunodeﬁciency, as produced by HIV-1, facilitates viral evasion
f immune response, thus resulting in the emergence of neoplastic
lones [7,8] (Table 1).
Initially, after the detection of viral products within neoplas-
ic cells, a single viral infection was considered fully responsible
or the oncogenic properties, while it is now established that in
any cases, multiple viral agents cooperate as cofactors in induc-
ng lymphomas, especially when herpesviral infections occur in the
resence of HIV-1 dependent immunodeﬁciency. As single tumor-
romoting agents, EBV and KSHV use a wide set of genes that
re involved in oncogenesis without the need to cooperate with
enes of other viruses. These genes include EBV EBNAs, LMPs,
ARF, and KSHV vFLIP and LANAs [9,10]. In some cases viruses
ct synergistically to promote lymphomagenesis; these coopera-
ion mechanisms are sustained by a more limited set of viral genes
hat may  target the same signaling pathway or interfere with the
eplication of coinfecting viruses.
Viruses cooperate by using all the above-mentioned patho-
enetic mechanisms in different combinations. The cooperation
etween KSHV and HIV deeply inﬂuences the risk for development
f KSHV-induced malignancies, i.e. KS, primary effusion lymphoma
PEL), and multicentric Castleman’s disease (MCD). Although these
isease entities display distinct features, KSHV-associated MCD  is
 tangle of these different entities, which are usually associated
ith HIV and KSHV infection [11]. In fact, MCD  has become increas-
ngly relevant in recent years thanks to its association with HIV and
SHV coinfections. Furthermore, while initially the major aspects
f virus dependent lymphomagenesis were concentrated on the
irect transforming activities of viral products on neoplastic cells,
here is now increasing evidence that the tumor microenvironment
lays an essential role in the development of lymphoid malignan-
ies [12].
The aim of this review is to describe how different viruses coop-
rate in the development of lymphomas, including the evidenceImpairment of T cell cytotoxic response
Evasion from innate and adaptive immune response
supporting their pathogenetic role, such as the techniques used
to demonstrate the presence of multiple viruses within the same
neoplastic cell and the description of the direct (i.e., transforming
ability) and indirect (i.e. immunosuppression and impact on the
microenvironment) mechanistic events that are involved in lym-
phomagenesis.
Finally, the therapeutic implications of viral cooperation mech-
anisms will be also discussed.
2. Viral cooperation
In the scientiﬁc literature, viral cooperation has been used to
describe different phenomena. For example, in their articles, Shi-
rogane et al. [13,14] deﬁned “cooperation” as a mechanism for viral
evolution, in which two  viral genomes produce a new phenotype
through a cooperative interaction between variant proteins (het-
erooligomer formation). This type of cooperation may  be subject
to positive selection even at a low multiplicity of infection, thus
providing an advantage of this new viral phenotype over the wild
type.
In this review that describes viral lymphomagenesis, we  deﬁne
viral cooperation as a mechanism by which different viruses coin-
fecting human tissues have synergistic or regulatory effects on
carcinogenesis.
Herpesviruses, once they have infected B lymphocytes, pro-
mote a lytic infection that may  be followed by the establishment
of latency; on the basis of local or generalized factors (i.e. the
presence of immunological defects), EBV has the special charac-
teristic to establish three different types of latency (types I, II and
III) that are represented in the various types of lymphomas [8].
Although the genes that are particularly expressed during latency
are considered essential for the transforming activity of the virus,
there is increasing evidence that the expression of lytic cycle genes
may  also have oncogenic consequences [15]. This observation is
particularly relevant for the scope of this review since, in the major-
ity of the cases, viral cooperation inﬂuences the balance between
the lytic and latent phases of the viral cycle or is able to modify
signaling pathways. Indirect mechanisms of cooperation, particu-
larly for HIV, are instead related to the ability to promote immune
dysregulation. In fact, the mechanism of viral cooperation is very
important in HIV-infected subjects, where a high degree of immu-
nodeﬁciency and/or inﬂammation is associated with the possibility
of being infected with multiple oncogenic viruses.
Finally, it is worth noting that cooperation in lymphomagene-
sis is not limited to viruses, but is a general mechanism that also
7 rs in Cancer Biology 34 (2015) 70–80
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Fig. 1. Primary effusion lymphoma (PEL) is a neoplasm characterized by KSHV infec-2 P. De Paoli, A. Carbone / Semina
nvolves other microorganisms, such as plasmodia, which play a
ole in inducing African EBV+ Burkitt lymphomas [16].
. Evidence supporting a role for viral cooperation in
ymphomagenesis and deﬁnition of microenvironmental
bnormalities
The conﬁrmation of a pathogenetic role of viral cooperation
n inducing lymphomagenesis is a complex process that requires
he detection of different viruses in the same neoplastic cells,
he demonstration of viral-dependent molecular alterations induc-
ng neoplastic transformation, and proof that immunodeﬁciency
nd/or chronic antigenic stimulation act in an indirect way  in pro-
oting tumor outgrowth. The demonstration of the mechanisms
nvolved in lymphomagenesis has been mostly obtained by using
ell lines, animal models and human neoplastic tissues. Due to the
ifﬁculty of reproducing in vitro tumor microenvironment, human
issue research has been also essential to deﬁne methods able to
recisely track the composition and functions of tumor microenvi-
onment.
. Detection of viral infection in cancer cells by molecular
ethods
The ﬁrst step to establish that viruses cooperate in inducing
umors is necessarily the demonstration through using appropriate
ethods that multiple viruses infect neoplastic cells.
. Detection of EBV infection
In EBV latently infected cells, EBER 1 and EBER 2 represent the
ost abundant viral transcripts. Therefore, in situ hybridization
ISH) targeting one or both EBERs is the gold standard assay for
eliably detecting EBV infection on formalin-ﬁxed tumor samples
17]. To identify the pattern of EBV latency expressed by tumor cells,
he expression of EBV latent genes can be assessed by immunohis-
ochemistry on ﬁxed tissue samples by analyzing EBV LMP1 and
BNAs [18]. Some studies have employed PCR to amplify EBV DNA,
ut this technique is subject to both false positive and false neg-
tive results and thus cannot be considered appropriate to deﬁne
n oncogenic role of EBV in tissues [19]. Recent studies suggest
hat EBV genome chips covering the entire viral genome have the
dvantage of a low false-positive rate and allows the simultaneous
nalysis of genome-wide viral gene expression pattern in tumor
issues. Finally, molecular methods have demonstrated the mono-
lonal nature of EBV infection in EBV associated cancers, a ﬁnding
hat implicates a critical role of this virus in oncogenesis [17].
Over the last few years EBV DNA in the peripheral blood has
een used extensively for the prediction, diagnosis and monitoring
f EBV-associated cancers. Depending on the type of EBV associated
ancer, EBV viremia has been considered as a tumor biomarker or
s a measure of the degree of immunosuppression [20].
. Detection of KSHV infection
The detection of KSHV infection in tumor cells is the prereq-
isite for a precise diagnosis of KS or PEL. The presence of KSHV
an be ascertained by immunohistochemistry on cells or sections
sing antibodies against the KSHV latency-associated nuclear anti-
en encoded by viral open reading fragment (ORF) 73 (Fig. 1). As
SHV in tumor cells is in the latent phase, ORF73 immunohisto-
hemistry is the gold standard to detect KSHV infection reliably on
umor samples [21].
The presence of KSHV can be conﬁrmed by PCR analysis [22,23].
nly a proportion of PEL tumors were found to be monoclonallytion  of the tumor clone as shown (1A) by nuclear staining with anti latent nuclear
antigen (LANA) antibody. PEL is composed of large cells that morphologically bridge
immunoblastic an anaplastic features (1B).
infected with KSHV, while the other cases had a biclonal or an
oligoclonal pattern of KSHV episomes. The apparent discrepancy
between viral and cellular clonalities in PEL might be due to
complex mechanisms of genomic recircularization, insertion of
duplicated sequences and simultaneous infection of tumor cells
with defective KSHV variants [24].
Positive cases can also be tested for viral interleukin-6 (vIL-6), a
KSHV cytokine homologue. Staining for vIL-6 is cytoplasmic and is
restricted to a limited number of infected cells. Positive controls for
ORF73 consist of KS biopsy samples, whereas positive controls for
vIL-6 consist of AIDS-associated MCD  biopsy samples [25]. During
KSHV infection viral DNA can be detected both in peripheral blood
mononuclear cells and as cell free DNA (viremia). Elevated KSHV
viremia is considered as a useful prognostic indicator of shorter
survival in PEL [26].
7. Detection of immune microenvironmental
abnormalities
Immune cells, such as reactive T-cells, B cells and macrophages
contribute to the tumor microenvironment. Soluble molecules also
play an essential role in the development of lymphomas, both in
the human immunodeﬁciency virus (HIV−) and in the HIV+ sub-
jects Si intended in both HIV− and HIV+ subjects? HIV infection
causes a profound perturbation of cytokine levels; this dysregula-
tion of cytokine pathways has an essential role in lymphomagenesis
[27]. The study of microenvironmental abnormalities is a recent
topic of research and deﬁnitive protocols aiming at investigating
this issue are still under scrutiny. Methods to study the microenvi-
ronment must take into account that the tumor microenvironment
includes different components, of which immune-derived cells
constitute the most relevant and dynamic component; by the use
of well known phenotypic markers and functional assays, Liapis
et al. [28] were able to deﬁne a microenvironment-associated panel
that exhaustively identiﬁes cells associated with the lymphoma
tumor microenvironment in HIV+ subjects. The immunopheno-
typic panel includes several CD3, CD4, CD8, CD56, CD68, CD163,
FOXP3, TIA1, granzyme B, perforin, CD57, CD34 and PD-1. Further-
more, the deﬁnition of different subsets of tumor macrophages
has been attempted recently by using functional, rather than phe-
notypic, measurements [29]. A second relevant immune-derived
microenvironmental component is constituted by soluble factors
such as cytokines (IL-1, IL-2, IL6, IL10, etc.) and by chemokines (such
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(ig. 2. Schematic representation of lymphoma microenvironment including immun
on-immune components (ﬁbroblasts, stromal cells, blood vessels). The Figure incl
s those included in the CCL and CXCL families). Studies investigat-
ng the role of cytokines as prognostic factors on peripheral blood
amples have given important information on lymphomagenesis
30]; future studies including biomarker measurements on tissue
pecimens may  be useful to deﬁne more clearly the role of immune
umor microenvironment in the development of virus-driven lym-
homas. The role of tissue-soluble molecule on the development
f lymphomas can be assessed by several immunological methods,
uch as ﬂow cytometry on lymphoma cell suspensions or in situ
ethods on neoplastic tissue samples. Tissue samples may  be also
nvestigated by molecular assays targeting the expression of vari-
us biomarkers.
In the last few years, there has been increasing recognition of
he importance of HIV-1 interactions with the microenvironment.
ntracellular HIV-1 infection can be demonstrated in the immune
icroenvironment by detection via the immunohistochemistry of
iral proteins or nucleic acids; due to its abundance, the majority
f the studies targeted intracellular p24 by ELISA or ﬂow cytometry
31]. The study of low copy HIV-1 DNA by in situ hybridization has
ome limitations due to sensitivity issues, therefore, in situ poly-
erase chain reactions have been used to detect intracellular HIV-1
NA, but this technique was seldom used [32]. Huysentruyt et al.
ound that 60% of HIV-associated lymphomas had macrophages
tained for intracellular p24 protein, thus suggesting a role for these
nfected cells in the development of these tumors, possibly by their
roinﬂammatory activity [33].
. Non-immune microenvironmental abnormalities
The abnormalities of non-immune microenvironments also
ontribute to the development of malignant cells. In lymphomas,
he non-immune microenvironment is composed of endothe-
ia, stromal cells, and ﬁbroblasts. These aspects were mostly
nvestigated in the context of virus-independent lymphomage-
esis [12,34], while few data are available on viral-associated
ymphomas. Recently, Liapis et al. found that the process of neovas-
ulature was increased in AIDS-related lymphomas as compared
o NHL arising in the general population; in viral-infected tis-
ues, microvessel density was correlated with EBV expression
see below). It is worth noting that an impact on neovasculatureponents (CD4 and CDT lympocytes, macrophages, cytokines and chemokines) and
iruses and their products that inﬂuence the microenvironment.
may  also be considered as a general event in other viral asso-
ciated pathological conditions. In fact, several viruses, such as
cytomegalovirus and viruses causing hemorrhagic encephalitis, are
able to infect endothelial cells, alter their functions and modify
the microenvironment. These modiﬁcations may be of particular
interest in infectious disease pathogenesis.
Recent studies in DLBCL have demonstrated that two gene signa-
tures had prognostic signiﬁcance: on one side a favorable outcome
was associated with genes encoding extracellular matrix proteins
(ﬁbronectin, collagen, laminins), and on the other side enrichment
in genes related to endothelial cells and functions or to angiogenesis
predict poor outcomes [35]. These data mostly relate to lymphomas
that are not associated with viral lymphomagenesis, so no data are
presently available regarding a role, if any, of viruses either as sin-
gle agents or in combination in conditioning clinical outcomes in
viral-associated lymphomas.
The role of viruses in targeting the different components of the
tumor microenvironment is summarized in Fig. 2.
9. Viral-associated lymphomagenesis without evidence of
viral cooperation
Viral-associated lymphomagenesis may  rely on single viral pro-
moting agents, especially in HIV negative subjects. In the following
paragraphs, we  brieﬂy describe speciﬁc types of lymphomas in
which pathogenetic mechanisms rely on one rather than multiple
infecting viruses.
10. Post-transplant lymphoproliferative disorders (PTLD)
EBV is the only virus involved in PTLD lymphomagenesis,
probably because, differently from lymphomas arising in other
immunodeﬁciency states, transplanted subjects do not have con-
sistent epidemiological, serological and molecular evidences of
ongoing or past infections with other viruses that have a role in
promoting oncogenesis [36]. In PTLD, the most important cofactor
in the development of lympomagenesis is iatrogenic immunosup-
pression. In addition, it has been recently demonstrated by gene
expression proﬁling that, among PTLDs, there are viral and inﬂam-
matory response signatures that segregate with EBV-positive cases
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ut not with EBV-negative ones [37], thus suggesting that the
enetic background of the host may  also inﬂuence the ability of
his virus to promote lymphoproliferation.
1. Adult T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma is caused by HTLV-1, the ﬁrst
escribed human lymphotropic retrovirus [38]. In this disease,
ncogenesis is mediated entirely by HTLV-1 oncoproteins, although
he individual’s ability to control HTLV-1 infection and the cooper-
tion with certain parasites may  represent known cofactors [39].
resently, cooperation mechanisms involving HTLV-1 and other
iruses have not been investigated.
2. HCV-associated lymphomas
According to IARC, there is a two-fold excess risk of NHL in
ndividuals who are HCV infected, but HIV negative; thus, IARC
oncludes that there is sufﬁcient available evidence on the role
f HCV as a cause of B-cell non-Hodgkin lymphomas [7]. Despite
he fact that HCV is a lymphotropic virus that can be detected
ithin these cells, this virus does not have direct oncogenic effects,
ut acts mostly by stimulating B lymphocytes after interaction
etween HCV-E2 protein and the cellular receptor CD81 [6]. A
athogenetic cooperation between HIV and HCV has been sug-
ested to occur in the development of hepatocellular carcinomas
40,41], while, as far as the role of coinfecting viruses in HCV
ymphomagenesis is concerned, available data may  permit the
xclusion of a cooperative role of HIV on HCV lymphomagenesis; in
act, according to Terrier et al., anti-HCV treatment led to hemato-
ogical response in a HIV-1/HCV coinfected patient with lymphoma,
upporting the role of chronic antigenic stimulation by HCV on
ymphomagenesis [42]. The role of other viruses (i.e., EBV, KSHV)
as never been demonstrated. It’s worth noting that many studies
ave used seroepidemiological methods to establish causal asso-
iations between infecting viruses and lymphomas, a criteria that
uffers from several drawbacks because of the widespread diffusion
f these viruses in humans [19,43].
3. Viral cooperation and lymphomagenesis
The study of oncogenetic events related to viral cooperation
as been greatly facilitated by the availability of human lym-
homa/leukemia (LL) cell lines, while the availability of appropriate
nimal models is presently limited. In particular, the advent of LL
ell lines has been an invaluable tool for studying lymphomagen-
sis due to the fact that LL cell lines grow in huge quantities, thus
ffering enough material to perform practically every technique
ecessary to investigate the role of different viruses in lymphoma-
enesis; although some caveats may  limit the conclusions drawn
rom studies using LL cell lines, they maintain, almost permanently,
haracteristics similar to those of human cancer tissue cells [44].
nitially, this was  particularly important for EBV-related carcino-
enic mechanisms as a single viral infecting agent causing Burkitt
ymphomas. More recently, the use of LL cell lines derived from PEL
as been particularly important for the investigation of the role
f viral coinfections since these cell lines may  be dually infected
y KSHV and EBV, but also singly infected by KSHV [45,46]. Major
dvances in the deﬁnition of PEL pathogenesis have been gained
ith the characterization of gene expression proﬁling and pro-
eomics in single or dually infected cell lines [47,48].
One of the major hurdles in studying study viral lymphomagen-
sis and the role of the immune microenvironment is represented
y the paucity of affordable animal models. One approach to over-
oming this limitation is the establishment of mice models withancer Biology 34 (2015) 70–80
transferred or reconstituted human immune system. These mod-
els are usually based on mouse strains that lack murine immune
system development due to genetic lesions and that have been
reconstituted with human CD34+ hematopoietic stem cells (HIS
mice). Herpesviral infections have been extensively studied using
HIS mice [reviewed in [49]] and, in particular, several types of
lymphoproliferative disorders have been obtained by infecting HIS
mice with EBV, although the pattern of viral latency, the immune
response and the aggressiveness of the tumors may vary consis-
tently in different experiments [49,50]. Similar studies using KSHV
have suggested that viral infection in the absence of sufﬁcient
lymphocyte reconstitution is minimal. Furthermore, no associated
KSHV pathology has been reported in this case, thus suggesting
that KSHV-associated malignancies are difﬁcult to be reproduced
in HIS mice [49,51]. Despite the signiﬁcant advances in understand-
ing lymphomagenesis, many hurdles still limit the use of HIS mice
for the study of human immune response and lymphomagene-
sis [49]. In particular, the immunomodulating properties of viral
coinfections and the putative role of viral cooperation in causing
lymphomas have never been investigated with these models.
A current view of viral coinfections in HIV-associated human
lymphoma tissues is depicted in Table 2.
14. Mechanisms of viral cooperation in lymphomagenesis
14.1. HIV and EBV
Early in the course of HIV infection, HIV and EBV establish a
delicate balance. In fact asymptomatic HIV+ patients harbor ele-
vated levels of EBV DNA in peripheral blood, probably reﬂecting a
high number of EBV-infected B cells that are not efﬁciently cleared
due to immunosuppression. These high viral levels, however, are
not predictive of the development of EBV+ lymphomas, nor with
the progression of HIV disease [52,53]. This probably depends on
the repeated observations demonstrating that these points of EBV
DNA load are greatly variable among subjects [54]. It has been con-
cluded that HIV’s effects on EBV load are not an effect of reduced
immune control, but rather a consequence of increased immune
activation and of changes in the composition of B-cell subpopula-
tions in peripheral blood [16,55]. These alterations are not limited
to the peripheral blood because the architecture of the lymphoid
tissues is also deeply disrupted by HIV infection. HIV-associated
lymphomas include a wide spectrum of different types.
Different histological types of NHL three have been associated
with AIDS-deﬁning malignancies in the pre-HAART era, by the 1985
deﬁnition of the Centers for Disease Control: diffuse large B-cell
lymphoma (DLBCL) with immunoblastic features; primary central
nervous system lymphoma (PCNSL); and Burkitt lymphoma (BL).
The terminology for lymphomas has changed since then, and it is
accepted that DLBCL of either the germinal center subgroup or acti-
vated B-cell subgroup can be considered AIDS-deﬁning. Hodkgin
lymphoma (HL) was also observed, but it was less frequent.
After HAART, the incidence of NHL declined but not as dramati-
cally as KS. The incidence of NHL declined by 77% in the post-HAART
era (1996–2007) as compared to the pre-HAART era (1984–1995)
[56].
HAART was particularly effective at reducing the incidence of
PCNSL and immunoblastic DLBCL, but it appeared to have less
impact on the incidence of BL. EBV-associated DLBCL remains the
main type of cancer in HIV-infected people, but the incidence of
other EBV-associated lymphomas such as BL, HL, PEL and plas-
mablastic lymphoma of the oral cavity type still remains high [57].
From these data it may  be hypothesized that different pathogenetic
mechanisms may  be active in the different NHL subtypes, including
cooperation between viruses.
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Table  2
A current view of viral coinfections in HIV-associated human lymphoma tissues.
Lymphoma type EBV, % Latency KSHV KSHV genes
BL with plasmacytoid differentiation +60 I Neg
Diffuse large cell lymphoma and immunoblastic plasmacytoid variant +90 II/III Neg
PEL  and solid variants +90 I +100% LANA, orf71, orf72, orf k12
Plasmablastic lymphoma of the oral cavity +80 0/I Neg
Large  B cell lymphoma arising in Multicentric Castleman Disease Neg Neg +100% LANA, v-IL6
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HD  
In vitro studies have demonstrated in cell-line models that EBV
nd HIV have consistent reciprocal molecular interactions that may
odulate their pathogenetic characteristics. In fact, it has been
emonstrated that EBV, through the EBNA-2 gene, causes a sig-
iﬁcant activation of HIV-1 LTR, thus promoting HIV replication
58]; functional deletion experiments demonstrated that EBNA-2
xerts its activity by inducing NF-kb factors [58]. The opposite, i.e.,
hat HIV-1 modulates EBV functions may  also be true; in fact, sev-
ral experimental data have suggested that the HIV-1 tat protein
ight be involved in the pathogenesis of B-cell lymphomas. This
rotein has been found in HIV-associated B-cell lymphoma tissues
59]. In vitro experiments showed that tat modulates cell prolifer-
tion and apoptosis of EBV-immortalized cell lines suggesting that
ells expressing tat have growth advantage among the EBV-driven
ell proliferation and may  give rise to clones with higher oncogenic
otential [60]. Since not all cases of Burkitt lymphomas in HIV-1+
ubjects are EBV+, as happens in endemic BL tumors, this type of
ymphoma could be considered an exception to the viral coopera-
ion model of lymphomagenesis. According to Rickinson et al. [16]
his may  be partly due to a lower EBV viral load in the early course
f HIV disease, as compared to African children who  will develop
L. Infection with Plasmodium falciparum in African BL cases may
ause a potent proinﬂammatory stimulus, that in turns promotes
BV replication and oncogenesis.
Since indirect effects of viral cooperation are difﬁcult to
rove, the relationship between HIV-dependent alterations of
he immune microenvironment and the development of EBV-
ssociated lymphomas need to be further investigated. In fact,
iapis et al. [28] demonstrated that in AIDS-related DLBCL there is a
ubstantial decrease of CD4 counts in the peripheral blood (median
5.5 cells/mmc), while AIDS associated BL and HD are character-
zed by a moderate immunodeﬁciency, that is 200–500 CD4/mmc
n Burkitt’s lymphoma [16]. Peripheral blood lymphocyte counts do
ot exactly reﬂect the degree of immunodeﬁciency since they are
nﬂuenced by the sequestration of lymphocytes at the tumor site;
herefore, studies on local tumor microenvironments are required
o make appropriate correlations between the degree of immuno-
eﬁciency and the development of different lymphoma types [28].
Besides the well-known HIV-1 capacity to deplete CD4 T-
ells, causing immunodeﬁciency, there are other viral-dependent
echanisms impacting the immune tumor microenvironment.
or example, both EBV and HIV are able to induce the expres-
ion of PD-L1 on antigen presenting cells [61,62]. PD-L1 is an
mmunomodulatory molecule that selects tumor cells engaging
eceptors on T-cells, thus resulting in inhibition of T-cell immunity;
his engagement compromises the ability of the immune system to
lock tumorigenesis. The interaction between HIV and EBV may
e also mediated by tissue macrophages. Long-lived macrophages
epresent a reservoir for HIV; the presence of this virus within
acrophages is established by staining of the HIV p24 protein; p24+
acrophages are present in approximately 50% of AIDS-associatedymphomas [63]. A proportion of these lymphomas also harbor EBV,
ut this virus has not been shown to infect macrophages, at least
n these tumors. Preclinical data in SCID mice support the lym-
homagenic potential of HIV-infected macrophages [63], whichI/II/III Neg
 II Neg
is probably related to their proinﬂammatory activity, while viral
coinfections do not have a role.
Both HIV-1 and EBV are able to induce proinﬂammatory
cytokines and to perturb the secretion of other immunomodulatory
molecules, thus inﬂuencing cellular proliferation, apoptosis and
other physiological functions related to the microenvironment. In
particular, the HIV-1 dependent switch from a Th1 to a Th2 pattern
of CD4 T-cell subpopulations has been considered as an important
step in the pathogenesis of immune dysregulation [64]. The non-
immune microenvironment is also affected by viral cooperation
mechanisms. Liapis et al. [28] found that the amount of neovascu-
lature was consistently higher in AIDS NHL than in sporadic NHLs;
furthermore, in AIDS NHL microvessel density was positively corre-
lated with EBV status as measured by EBER expression, although the
possible EBV dependent pathogenetic mechanisms have not been
investigated. A putative mechanism linking EBV to angiogenesis has
been described by Kondo et al., who have previously suggested that
signaling by EBV LMP-1 may  promote angiogenesis by upregulating
the HIF1 factor resulting in the hyperproduction of VEGF [65]. It is
worth noting that the interaction between viruses and angiogenesis
is part of a more general mechanisms regarding also non neoplas-
tic diseases; in fact several other viral species (i.e. cytomegalovirus,
viruses causing hemorrhagic fevers or encephalitis) impact angio-
genesis by infecting endothelial cells, thus altering their functions
and modifying tumoral microenvironment.
14.2. HIV and KSHV
Evidence points to a direct cooperative role of HIV-1 in tumori-
genesis that is independent on its immunosuppressive effects. In
fact, HIV-1 infection of a PEL cell line triggers KSHV reactivation
[66]. In these cells, reactivation of KSHV was obtained by tran-
sient expression of HIV tat,  while recombinant HIV envelope gp120
protein had no effect. Mercader et al. [67] demonstrated that the
opposite could be also true, because KSHV induces HIV-1 replica-
tion within CD4 T-cells in vitro and in vivo in an animal model, thus
resulting in increased HIV viral load that is followed by a worsening
of the immune deﬁciency.
To better elucidate the mechanisms that drive reciprocal inter-
actions between HIV-1 and KSHV, Huang et al. fused the KSHV+
PEL cell line BCBL-1 with the HIV-1 positive ACH2 cells [68]. These
experiments indicated that, when both viral genomes are present
in the same cellular environment, there is a bilateral positive trans-
criptional effect between the two viruses. In particular, the KSHV
KIE2 protein was  able to induce transcription from the HIV-1 LTR,
while on the other side, HIV-1 tat and vpr proteins individually
activated KSHV transcription. These authors suggested that their
ﬁndings may  explain why  there is an increased risk of developing
viral associated cancers in dually infected subjects; they also pos-
tulated that a pharmacological interruption of both viral cycle(s)
may be used to target these tumors therapeutically. As far as
oncogenic viruses are concerned, lymphatic endothelial cells are
readily infected by KSHV and play an essential role in the induc-
tion of neoangiogenesis in PEL. Presently, it is debated whether
HIV-1 may  inﬂuence neoangiogenesis in the microenvironment by
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roductively infecting endothelial cells. Currently available exper-
mental data are in favor of an active role of HIV-1, and hypothesize
hat this virus may  promote angiogenesis through the tat pro-
ein that stimulates capillary formation [28]. Another HIV protein,
17, promotes angiogenesis via a different mechanism involving
he engagement of chemokine receptors [69]. In fact, the HIV-1
atrix protein p17 after its release from infected cells and binding
o CXCR1, was found to exert an interleukin IL-8, chemokine-like
ctivity on human monocytes, thus promoting their trafﬁcking
nd sustaining inﬂammatory processes. A haplotype of the CXCR1
ene (CXCR1 300 142) has been associated with slow HIV-1 disease
rogression, herein calling for an exploration of the therapeu-
ic potential of blocking the p17/CXCR1 axis in HIV infection
70]. Despite this promising evidence, the precise contribution of
irus-driven angiogenetic mechanisms in the development and
rogression of viral associated lymphomas is still under scrutiny
nd deserves further study.
The above-mentioned experimental data suggest that reciprocal
nteractions between HIV-1 and KSHV occur according to complex
echanisms involving multiple genes and proteins. At the moment,
tudies on this topic have not been further extended and there-
ore the relevance of KSHV-HIV-1 interactions in inducing human
umors is still not deﬁned.
4.3. HIV, EBV and KSHV
The most relevant viral cooperation includes cancers where
hree viruses, HIV, EBV and KSHV, exert cooperative oncogenic
ffects. Although also occurring also in the HIV negative subjects,
EL is the prototypic lymphoma type that develops in HIV-1 sub-
ects EBV and KSHV coinfect tumor cells [8]. In order to understand
heir contribution to the pathogenesis of PEL, it is essential to
nvestigate how both viruses interact. As mentioned before, viral
ooperation may  inﬂuence the balance between lytic and latent
hases of the viral cycle. Lytic cycle activation of EBV is controlled
y two transcription factors, ZEBRA and Rta, while the KSHV ORF50
ncodes an homologue of EBV Rta [71]. Viral lytic reactivation
equires the formation of a complex between Rta and the RPB-
k host protein, which is necessary for the latent transformation
f EBV-infected B lymphocytes. Previous reports have shown that
hese two herpesviruses interact at the molecular level to promote
ach other’s latency in the same tumor cells, especially in PELs
72,73]. KSHV RTA potentiates EBV latency via induction of LMP-1,
hile LMP-1 itself blocks KSHV lytic replication. This means that a
egulatory loop exists between these two herpesviruses that rein-
orces each other’s latency in the tumor cells which may  contribute
o establishing/maintaining tumor cells in PEL [72]. Of note, these
xperimental data have been obtained by using EBV or KSHV singly
nfected cells, thus raising concerns about the applicability of these
tudies in dually infected PELs.
Based on these ﬁndings, Spadavecchia et al. studied reciprocal
ooperation in EBV KSHV dually infected cell lines: their data sug-
est that KSHV and EBV cooperate to stimulate PEL cell growth by
 mechanism in which KSHV Rta induces cellular growth by direct
nteraction with the RPB JK cellular protein and by transactivating
BV-dependent latency genes [74]. Collectively these data reinforce
he notion that interactions between viral and cellular machineries
re complex and multifactorial.
By using a different model, it has been shown that the coop-
ration of EBV and KSHV is also exerted by interference with
echanisms interfering with the proliferation of PEL cell lines. In
act EBV, by inhibiting the EBNA-1 expression to induce the loss of
BV from these cells, also inhibits their proliferation and colony for-
ation [47]. In the same way, KSHV is also necessary to maintain
ellular proliferation through the LANA protein [75]. The balance
f KSHV and EBV in PEL is very delicate, since this type of tumorancer Biology 34 (2015) 70–80
requires a low, but sufﬁcient, amount of EBNA-1 to maintain cellu-
lar growth.
Possible mechanisms for HIV EBV KSHV interactions do exist
and target HIV LTR, which increases HIV-1 replication. KSHV ORF50
interacted synergically with tat,  inducing a 10-fold enhancement
of HIV-1 LTR transactivation. This effect occurred both in BCBL-1
cells latently infected with HHV-8, and in HL3T1 cells, an epithe-
lial cell line non-permissive to HHV-8 infection. [76]. In another
experimental setting, the abilities of various KSHV proteins to acti-
vate gene expression from the HIV-1 LTR have been investigated,
demonstrating that KSHV ORF45 is the most potent LTR activa-
tor. ORF45 is known to induce cell signaling through ribosomal S6
kinase (RSK) and enhance protein translation. However, the activa-
tion of a speciﬁc isoform of RSK by ORF45 also leads to increased
mRNA synthesis from the LTR by the host RNA polymerase [77].
All the above-mentioned in vitro experimental data point out a
role of viral cooperation in the development of PEL and other lym-
phoproliferations associated with KSHV. The importance of these
mechanisms should be further investigated within in vivo systems,
such as animal models and human neoplastic cells.
15. Modulation of genes involved in oncogenesis
Both EBV and KSHV modulate NFkB signaling [78]. The NFkB
pathway is involved in the viral life cycle and is constitutively
activated in EBV and KSHV-associated lymphomas. EBV is able to
activate NFkB after interaction with its surface receptor CD21 on
B cells and with the LMP-1 protein; KSHV exerts its activity by
different mechanisms involving the viral FLICE latent cycle regu-
latory protein and several proteins of the lytic viral cycle. Thus,
both viruses converge their tumor-promoting activities on NFkB
signaling, which in turns is able to inhibit apoptosis and increase
cell proliferation. This observation suggests a rationale for the use
of NFkB inhibitors for therapeutic purposes.
The existence of a few KSHV+ EBV− PEL cell lines represents a
valuable tool to provide additional data on the role of EBV in PEL
pathogenesis. These EBV – cell lines were infected with EBV strains
[79] and this superinfection resulted in a restricted EBV latency
program, causing downregulation of surface antigens that were
responsible for increased tumorigenicity in SCID mice, while the
expression of TCL1, a gene that was demonstrated to have a puta-
tive in vitro oncogenic role in Burkitt lymphomas was unaffected
[79,80]. This study demonstrated that increased tumorigenicity of
dually infected PELs does not depend on TCL1activity.
The mechanisms that cause tumorigenicity after viral coinfec-
tion are still incompletely revealed and many mechanisms have
been recently proposed.
A very recent paper has investigated the involvement of UCHL1,
a cysteine hydrolase that catalyzes hydrolysis of ubiquitin. While
mutations in the UCHL1 gene have been initially associated with
neurological diseases, its physiological functions are still incom-
pletely understood. Furthermore de novo expression of UCH-L1
has been detected in numerous cancer types [81], and this gene
has oncogenic properties and is highly expressed in several malig-
nancies. Bentz et al. demonstrated that KSHV infection induces
UCH-L1 expression through the ability of the LANA protein to acti-
vate the uch-l1 promoter. A similar increasing effect was realized
by EBV in dually infected primary PEL cells, which is mediated by
multiple viral products, such as EBNA1, LMP-1, and EBERs. Finally
KSHV LANA and LMP-1 cooperate in the induction of UCH-L1 in
PEL cells. The authors concluded that lymphomagenesis mediated
by both viruses rely, among other mechanisms, on the upregulation
of UCH-L1 expression.
Various Toll-like receptors (TLRs) are implicated in the early
interplay of host cells with invading viruses, resulting in the
P. De Paoli, A. Carbone / Seminars in C
Table  3
Most relevant genes and mechanisms involved in viral cooperation and oncogenesis.
Virus Gene Mechanisms involved
HIV Tat Activation of KSHV transcription
Modulation of apoptosis
Vpu Activation of KSHV transcription
EBV LMP-1 Activation of UCH-L1
Proliferation of KSHV coinfected cells
EBNA-2 Activation of HIV-1 LTR
KSHV KIE2
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LANA Activation of UCHL-1
odulation of viral replication and/or host responses, ultimately
mpacting viral pathogenesis [82]. Recent experiments suggest that
erpesviruses may  exert their lymphomagenic activities through
nteractions with TLRs; in fact, TLRs act as agonists inducing the
roliferation and activation of B cells by EBV [83] while KSHV
revents activation of the innate immune response by targeting
LR signaling [84]. Although direct demonstrations linking TLR
ignaling with viral-dependent lymphomagenesis are presently
ot available, it is possible that cells latently infected with her-
esviruses will encounter multiple pathogens during their lifetimes
nd that these encounters lead to cooperation mechanisms that
ay  promote lymphomagenesis.
The most relevant genes and mechanisms involved in viral coop-
ration and oncogenesis are reported in Table 3.
6. Lymphomagenesis related to the immune recovery
nﬂammatory syndrome (IRIS)
Recent data support the hypothesis that lymphomas arising in
he context of the immune reconstitution inﬂammatory syndrome
epresent a distinct entity. The deﬁnition of IRIS is still uncertain,
lthough it is usually considered as a syndrome occurring during
he ﬁrst six months of HAART with virological suppression. Gopal
t al. described 56 cases of HIV-1 associated lymphomas that met
he IRIS case deﬁnition [85]. These cases included Hodgkin lym-
homa as well as various subtypes of NHL occurring in patients with
evere to moderate immunodeﬁciency status (median CD4 count
as below 200 cells/mmc). Since no data on the viral status of these
ases was available, the authors concluded that examining EBV
tatus among these lymphomas may  be informative, particularly
ince other herpesviruses, including KSHV, are commonly impli-
ated in IRIS presentations. Also viruses causing chronic antigenic
timulation, such as viral hepatitis viruses, may  be relevant in the
evelopment of these lymphomas. Future studies may  investigate
ll these important issues.
7. Therapeutic implications of viral cooperation
The above-mentioned experimental data on viral cooperation in
nducing lymphomagenesis stimulated the establishment of novel
herapeutic strategies targeting viruses and the microenvironment.
he introduction of HAART to treat HIV infection has notably
hanged the natural history of HIV-associated lymphomas, that is
ainly attributed to the restoration of CD4 mediated immunity.
iapis et al., in comparing data from the pre-HAART period and post-
AART period of diffuse, AIDS-related large B-cell lymphomas,
ound higher numbers of CD4 T-cells and a reduction in EBER
xpression in post HAART tissue specimens, whereas the expres-
ion of other immune markers and of inﬁltrating macrophage
umbers was not signiﬁcantly changed [28]. It is not clear at this
oment whether these changes reﬂect modiﬁcations in the patho-
enesis and/or clinical outcome of HIV-1 associated lymphomas.ancer Biology 34 (2015) 70–80 77
After the demonstration that viruses, particularly HIV-1, pro-
mote angiogenesis in lymphomas, it has been suggested that
antiangiogenetic therapeutic combinations, such as those used to
treat solid cancers, may  also represent a promising approach to
treat viral associated lymphomas; presently, sporadic studies did
use monoclonal antibodies against the VEGF receptor to treating
viral-associated cancers [86], but no clear conclusions on the efﬁ-
cacy of this therapeutic approach are presently available.
As previously mentioned, NFkB activation is critical in the patho-
genesis of virally induced lymphomas, thus providing the rationale
for the therapeutic use of anti-NFkB inhibitors. However, there are
presently no descriptions of clinical trials using NFkB inhibitors in
viral associated lymphomas [78].
The recent knowledge about the importance of tumor microen-
vironments has led to the development of agents able to normalize
tumor microenvironment abnormalities speciﬁcally, then improv-
ing treatment outcomes. While trials using this approach gave
promising results in some solid cancers, none of these agents has
reached clinical application in viral-associated lymphomas [87,88].
18. Concluding remarks
Initially the major aspects of virus-driven lymphomagenesis
were concentrated on the direct transforming activity of single
viral oncogenic products, while now there is growing recognition
that cooperation among different viruses also plays an essential
role in the development, survival and dissemination of lymphoid
malignancies. For these reasons, the relationship between microen-
vironment, oncogenesis, tumor growth and dissemination has been
the topic of many investigations. Viral cooperation targets neoplas-
tic B cells as well as cells of the microenvironment, such as reactive
T-cells, B cells and macrophages, as well as non-immune cells such
as endothelial cells, that contribute to tumor microenvironment.
The most important viral genes involved in cooperation include
HIV-1 tat and vpu, EBV LMP-1 and EBNA-2 and KSHV KIE2, Rta
and LANA. The immune cellular inﬁltrate in AIDS NHLs reﬂects the
HIV-dependent cellular imbalances that have been described in the
peripheral blood. In fact, DLBCL HIV+ tissues contain fewer CD3+
T-cells, and display a marked reduction of CD4+ T-cells and CD8+
T-cells constitute the predominant T-cell inﬁltrate. In AIDS NHLs,
studies on non-immune microenvironmental components concen-
trated on neoangiogenesis. It has been found that neovasculature
was strikingly higher in AIDS NHL than in sporadic NHLs and that
in these tumors microvessel density was positively correlated with
EBV status as measured by EBER expression.
Virus-driven lymphomagenesis represents an interesting topic
where microenvironmental abnormalities may  be particularly
relevant, particularly because antiviral targeted therapies and ther-
apies producing the reconstitution of the immune system may
constitute areas of interest aiming at improving the outcome of
virus associated lymphomas. While the immune component of the
lymphoma microenvironment can be easily studied by immuno-
logical and molecular techniques, the deﬁnition of the non-immune
component of the lymphoma microenvironment is largely incom-
plete and may  be the issue of future investigations. Understanding
the pathogenetic role of viral infection in speciﬁc malignancies
and deﬁning microenvironmental abnormalities and mechanisms
of viral carcinogenesis are important steps toward precise diagnosis
and accurate treatment strategies for HIV-associated cancers.Conﬂicts of interest
The authors declare that there are no conﬂicts of interest.
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